Possibia

3861715

Last Update Posted: 2020-10-08

Recruiting status is unknown

Females

accepted

20 Years-34 Years

180 Estimated Participants

No Expanded Access

Observational Study

Accepts healthy volunteers

Single Follicular Dexarelix for LH Suppression During Ovarian Stimulation in Oocyte Donors.

A randomized prospective study in the evaluation of the long acting GnRH antagonist Degarelix against the classical multidose regime with Ganirelix for LH suppression during the follicular phase of an ovarian stimulation cycle in oocyte donors.

A randomized prospective study of the use of single dose of the long acting GnRH antagonist Degarelix for ovarian stimulation cycle in oocyte donors: Ovarian stimulation started on cycle Day2 with gonadotropins 175-300 IU and either GnRH antagonist single dose Degarelix or multidose GnRH antagonist Ganirelix initiated on Day6 of the stimulation cycle. Agonist triggering was used in both groups for oocyte maturation. Blastocyst formation rate and Live Birth Rates were estimated for both groups.

Eligibility

Relevant conditions:

Infertility

Premature Ovarian Failure

If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.

locations

Contact Information

Overall Contact

Evaggelos Papanikolaou, MD,PhD

drvagpapanikolaou@yahoo.gr

00302310424294

Data sourced from ClinicalTrials.gov